Emerging platforms using liquid biopsy to detect EGFR mutations in lung cancer

Chien Chung Lin, Wei Lun Huang, Fang Wei, Wu Chou Su, David T. Wong

Research output: Contribution to journalReview articlepeer-review

32 Citations (Scopus)


Advances in target therapies for lung cancer have enabled detection of gene mutations, specifically those of EGFR. Assays largely depend on the acquisition of tumor tissue biopsy, which is invasive and may not reflect the genomic profile of the tumor at treatment due to tumor heterogeneity or changes that occur during treatment through acquired resistance. Liquid biopsy, a blood test that detects evidence of cancer cells or tumor DNA, has generated considerable interest for its ability to detect EGFR mutations. However, its clinical application is limited by complicated collection methods and the need for technique-dependent platforms. Recently, simpler techniques for EGFR mutant detection in urine or saliva samples have been developed. This review focuses on advances in liquid biopsy and discusses its potential for clinical implementation in lung cancer.

Original languageEnglish
Pages (from-to)1427-1440
Number of pages14
JournalExpert Review of Molecular Diagnostics
Issue number11
Publication statusPublished - 2015 Nov 2

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine
  • Molecular Medicine
  • Molecular Biology
  • Genetics


Dive into the research topics of 'Emerging platforms using liquid biopsy to detect EGFR mutations in lung cancer'. Together they form a unique fingerprint.

Cite this